Multifocal motor neuropathy (mmn)
Drug research and approvals for multifocal motor neuropathy (mmn): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 1 studies of multifocal motor neuropathy (mmn) are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 1
- Trials authorized in Canada: 5
- FDA orphan approvals: 1
- EU medicines: 0
Recruiting Now
Newest start dates first, of 1 recruiting on ClinicalTrials.gov ↗- A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor…NCT07610564 · Phase 1 · argenx · starts Jul 27, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Jun 18, 2026 | An open-label, single-arm, phase 1b study to evaluate the effect of empasiprubart on nerve morphology by ultrasound in adults with multifocal motor neuropathyEMPASIPRUBART (ARGX-117) | argenx US, Inc. | Pending |
| May 16, 2025 | A phase 3, randomized, double-blinded, double-dummy study evaluating the efficacy and safety of empasiprubart versus intravenous immunoglobulin in adults with…EMPASIPRUBART (ARGX-117) / OCTAGAM / SODIUM CHLORIDE | argenx US, Inc. | Ongoing |
| Apr 23, 2025 | A phase 2, randomized, double-blinded, placebo-controlled, study to evaluate safety, tolerability, pharmacometrics, and efficacy of dnth103 in adults with…DNTH103 | DIANTHUS THERAPEUTICS, INC | Ongoing |
| Nov 3, 2022 | A long-term extension of the argx-117-2002 trial to evaluate the long-term safety and tolerability, efficacy, pharmacodynamics, pharmacokinetics, and…ARGX-117 | argenx US, Inc. | Closed |
| Jan 12, 2022 | A phase 2, randomized, double-blinded, placebo-controlled, parallel-group, multicenter trial to evaluate the safety and tolerability, efficacy,…ARGX-117 | argenx US, Inc. | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Jun 22, 2012 | Gammagard LiquidMaintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN). | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Jun 5, 2024 | empasiprubarttreatment of multifocal motor neuropathy | argenx BV | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA